
Opinion|Videos|February 14, 2025
MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors
Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.
Advertisement
Episodes in this series

- Provide an overview of the current landscape of induction therapies for MCL. What role do BTK inhibitors have in this landscape?
- Aggressive induction therapy
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5